Janna Schoenmaekers1, Paul Hofman2, Gerben Bootsma3, Marcel Westenend4, Machiel de Booij5, Wendy Schreurs6, Ruud Houben7, Dirk De Ruysscher7, Anne-Marie Dingemans1, Lizza E L Hendriks8. 1. Dept. of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands. 2. Dept. of Radiology, Maastricht University Medical Center+, Maastricht, the Netherlands. 3. Dept. of Pulmonary Diseases, Zuyderland Hospital Heerlen, Heerlen, the Netherlands. 4. Dept. of Pulmonary Diseases, VieCuri Hospital, Venlo, the Netherlands. 5. Dept. of Radiology, Zuyderland Hospital Heerlen, Heerlen, the Netherlands. 6. Dept. of Nuclear Medicine, Zuyderland Hospital Heerlen, Heerlen, the Netherlands. 7. Dept. of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands. 8. Dept. of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands. Electronic address: lizza.hendriks@mumc.nl.
Abstract
INTRODUCTION: Non-small-cell lung cancer (NSCLC) guidelines advise to screen stage III NSCLC patients for brain metastases (BMs), preferably by magnetic resonance imaging (MRI) or when contraindicated or not accessible a dedicated contrast enhanced-computed tomography (dCE-CT), which can be incorporated in the staging 18Fluodeoxoglucose-positron emission tomography (18FDG-PET-CE-CT). In daily practice, often a dCE-CT is performed instead of a MRI. The aim of the current study is to evaluate the additive value of MRI after dCE-CT, incorporated in the 18FDG-PET-CE-CT. PATIENTS AND METHODS: It is an observational prospective multicentre study (NTR3628). Inclusion criteria included stage III NSCLC patients with a dCE-CT of the brain incorporated in the 18FDG-PET and an additional MRI of the brain. Primary end-point is percentage of patients with BM on MRI without suspect lesions on dCE-CT. Secondary end-points are percentage of patients with BM on dCE-CT and percentage of patients with BM ≤ 1 year of a negative staging MRI. RESULTS: Sixteen (7%) patients with extracranial stage III had BM on dCE-CT and were excluded. One hundred forty-nine patients were enrolled. 7/149 (4.7%) had BM on MRI without suspect lesions on dCE-CT. One hundred eighteen patients had a follow-up of at least 1 year (four with BM on baseline MRI); eight of the remaining 114 (7%) patients developed BM ≤ 1 year after a negative staging brain MRI. CONCLUSION: Although in 7% of otherwise stage III NSCLC patients, BMs were detected on staging dCE-CT, MRI brain detected BMs in an additional 4.7%, which we consider clinically relevant. Within 1 year after a negative staging MRI, 7% developed BM.
INTRODUCTION:Non-small-cell lung cancer (NSCLC) guidelines advise to screen stage III NSCLCpatients for brain metastases (BMs), preferably by magnetic resonance imaging (MRI) or when contraindicated or not accessible a dedicated contrast enhanced-computed tomography (dCE-CT), which can be incorporated in the staging 18Fluodeoxoglucose-positron emission tomography (18FDG-PET-CE-CT). In daily practice, often a dCE-CT is performed instead of a MRI. The aim of the current study is to evaluate the additive value of MRI after dCE-CT, incorporated in the 18FDG-PET-CE-CT. PATIENTS AND METHODS: It is an observational prospective multicentre study (NTR3628). Inclusion criteria included stage III NSCLCpatients with a dCE-CT of the brain incorporated in the 18FDG-PET and an additional MRI of the brain. Primary end-point is percentage of patients with BM on MRI without suspect lesions on dCE-CT. Secondary end-points are percentage of patients with BM on dCE-CT and percentage of patients with BM ≤ 1 year of a negative staging MRI. RESULTS: Sixteen (7%) patients with extracranial stage III had BM on dCE-CT and were excluded. One hundred forty-nine patients were enrolled. 7/149 (4.7%) had BM on MRI without suspect lesions on dCE-CT. One hundred eighteen patients had a follow-up of at least 1 year (four with BM on baseline MRI); eight of the remaining 114 (7%) patients developed BM ≤ 1 year after a negative staging brain MRI. CONCLUSION: Although in 7% of otherwise stage III NSCLCpatients, BMs were detected on staging dCE-CT, MRI brain detected BMs in an additional 4.7%, which we consider clinically relevant. Within 1 year after a negative staging MRI, 7% developed BM.
Authors: Lawek Berzenji; Sophie Debaenst; Jeroen M H Hendriks; Suresh Krishan Yogeswaran; Patrick Lauwers; Paul E Van Schil Journal: Transl Lung Cancer Res Date: 2021-07
Authors: Janna Josephus Anna Oda Schoenmaekers; Marthe Sentijna Paats; Anne-Marie Clasina Dingemans; Lizza Elisabeth Lucia Hendriks Journal: Transl Lung Cancer Res Date: 2020-12
Authors: Simon A Keek; Esma Kayan; Avishek Chatterjee; José S A Belderbos; Gerben Bootsma; Ben van den Borne; Anne-Marie C Dingemans; Hester A Gietema; Harry J M Groen; Judith Herder; Cordula Pitz; John Praag; Dirk De Ruysscher; Janna Schoenmaekers; Hans J M Smit; Jos Stigt; Marcel Westenend; Haiyan Zeng; Henry C Woodruff; Philippe Lambin; Lizza Hendriks Journal: Ther Adv Med Oncol Date: 2022-08-22 Impact factor: 5.485
Authors: Janna J A O Schoenmaekers; Jeroen Bruinsma; Claire Wolfs; Lidia Barberio; Anita Brouns; Anne-Marie C Dingemans; Lizza E L Hendriks Journal: JTO Clin Res Rep Date: 2022-08-27